Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Kidney Blood Press Res ; 44(6): 1383-1391, 2019.
Article in English | MEDLINE | ID: mdl-31618744

ABSTRACT

BACKGROUND: Unplanned start of renal replacement therapy is common in patients with end-stage renal disease and often accomplished by hemodialysis (HD) using a central venous catheter (CVC). Urgent start using peritoneal dialysis (PD) could be an alternative for some of the patients; however, this requires a hospital-based PD center that offers a structured urgent start PD (usPD) program. METHODS: In this prospective study, we describe the implementation of an usPD program at our university hospital by structuring the process from presentation to PD catheter implantation and start of PD within a few days. For clinical validation, we compared the patient flow before (2013-2015) and after (2016-2018) availability of usPD. RESULTS: In the 3 years before the availability of usPD, 14% (n = 12) of incident PD patients (n = 87) presented in an unplanned situation and were initially treated with HD using a CVC. In the 3 years after implementation of the usPD program, 18% (n = 18) of all incident PD patients (n = 103) presented in an unplanned situation of whom n = 12 (12%) were treated with usPD and n = 6 (6%) with initial HD. usPD significantly reduced the use of HD by 57% (p = 0.0005). Hospital stay was similar in patients treated with usPD (median 9 days) compared to those with elective PD (8 days), and significantly lower than in patients with initial HD (26 days, p = 0.0056). CONCLUSIONS: Implementation of an usPD program reduces HD catheter use and hospital stay in the unplanned situation.


Subject(s)
Central Venous Catheters , Kidney Failure, Chronic/therapy , Length of Stay , Peritoneal Dialysis/methods , Renal Dialysis , Catheterization/methods , Catheterization/standards , Female , Humans , Male , Middle Aged , Peritoneal Dialysis/standards , Prospective Studies , Renal Dialysis/instrumentation
2.
BMC Infect Dis ; 15: 464, 2015 Oct 27.
Article in English | MEDLINE | ID: mdl-26503619

ABSTRACT

BACKGROUND: Nephropathia epidemica (NE) is a mild form of hemorrhagic fever with renal syndrome (HFRS) that is caused by the Puumala virus. Periodic outbreaks have been described in endemic areas, with a substantial number of previously healthy individuals developing acute kidney injury (AKI). There is a considerable diversity in the clinical course of the disease, and few patients require renal replacement therapy. METHODS: We tested whether urinary neutrophil gelatinase associated lipocalin (uNGAL), urine albumin/creatinine ratio (uACR), urine protein/creatinine ratio (uPCR), urine dipstick protein, C-reactive protein, procalcitonin, leukocyte and platelet count, determined on admission to the hospital, can predict the severity of AKI. Sixty-one patients were analyzed during admission in the emergency department. RESULTS: The variables most strongly associated with peak plasma creatinine concentration were uNGAL (ß = 0.70, p <0.0001), uPCR (ß = 0.64, p = 0.001), uACR (ß = 0.61, p = 0.002), and dipstick proteinuria (ß = 0.34, p = 0.008). The highest AUC-ROC to predict stage 3 AKI according to the acute kidney injury network's (AKIN) classification was seen for uNGAL (0.81, p = 0.001). CONCLUSION: uNGAL accurately predicts the severity of AKI in NE. This could help emergency room physicians predict disease severity and allow for initial risk stratification.


Subject(s)
Acute-Phase Proteins/urine , Hemorrhagic Fever with Renal Syndrome/etiology , Lipocalins/urine , Proteinuria/etiology , Proto-Oncogene Proteins/urine , Puumala virus/pathogenicity , Acute Kidney Injury/etiology , Acute Kidney Injury/urine , Acute Kidney Injury/virology , Adult , Albuminuria/etiology , Biomarkers/blood , Biomarkers/urine , C-Reactive Protein/analysis , Calcitonin , Calcitonin Gene-Related Peptide , Creatinine/blood , Emergency Service, Hospital , Female , Hemorrhagic Fever with Renal Syndrome/virology , Humans , Lipocalin-2 , Male , Middle Aged , Protein Precursors , Retrospective Studies
4.
Dtsch Med Wochenschr ; 139(30): 1539, 2014 Jul.
Article in German | MEDLINE | ID: mdl-25072863

ABSTRACT

HISTORY AND ADMISSION FINDINGS: A 90-year-old female patient treated with dabigatran for atrial fibrillation presented emergently with a spontaneous vaginal bleeding due to endometrium carcinoma. INVESTIGATIONS: Laboratory analysis revealed azotemia consistent with acute-on-chronic renal failure. Coagulation was deranged (prolongation of activated partial thromboplastin time (aPTT) by 3.5-fold, international normalized ratio (INR) 7.8) due to a massive accumulation of dabigatran (measured plasma concentration 2230 ng/ml). DIAGNOSIS, TREATMENT AND COURSE: Vaginal bleedings were treated with external tamponade. Hemodialysis treatment was commenced due to uremia and dabigatran accumulation. Over night, the patient was dialysed with a SLED (sustained low efficiency dialysis) regimen. After volume resuscitation renal function promptly ensued indicating prerenal azotemia as a cause of renal failure. After two more hemodialysis sessions dabigatran concentrations were no longer detecable and this was paralleled by normalization of coagulation tests. CONCLUSIONS: Dabigatran can accumulate massively during acute renal failure and evoke a life-threatening bleeding diathesis. Dabigatran can be removed with low efficient dialysis (such as SLED).


Subject(s)
Antithrombins/adverse effects , Benzimidazoles/adverse effects , Uterine Hemorrhage/chemically induced , beta-Alanine/analogs & derivatives , Aged, 80 and over , Antithrombins/pharmacokinetics , Antithrombins/therapeutic use , Benzimidazoles/pharmacokinetics , Benzimidazoles/therapeutic use , Dabigatran , Diagnosis, Differential , Emergencies , Female , Humans , Kidney Failure, Chronic/complications , Metabolic Clearance Rate/physiology , beta-Alanine/adverse effects , beta-Alanine/pharmacokinetics , beta-Alanine/therapeutic use
5.
J Mol Med (Berl) ; 92(8): 871-9, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24743961

ABSTRACT

UNLABELLED: Anemia in end-stage renal disease (ESRD) results mainly from erythropoietin and iron deficiency. Anemia could be confounded, however, by accelerated clearance of circulating erythrocytes because of premature suicidal erythrocyte death or eryptosis characterized by phosphatidylserine exposure at the erythrocyte surface. Triggers of eryptosis include increased cytosolic Ca(2+) concentration ([Ca(2+)]i), oxidative stress, and ceramide. The present study explored whether and how ESRD influences eryptosis. Blood was drawn from healthy volunteers (n = 20) as well as ESRD patients (n = 20) prior to and after hemodialysis. Phosphatidylserine exposure was estimated from annexin V binding, [Ca(2+)]i from Fluo3-fluorescence, reactive oxygen species (ROS) from 2',7'dichlorodihydrofluorescein fluorescence, and ceramide from fluorescein-isothiocyanate-conjugated antibody binding in flow cytometry. Measurements were made in erythrocytes from freshly drawn blood and in erythrocytes from healthy volunteers exposed in vitro for 24 h to plasma from healthy volunteers or ESRD patients prior to and following dialysis. The patients suffered from anemia (hemoglobin 10.1 ± 0.5 g/100 ml) despite 1.96 ± 0.34 % reticulocytes. The percentage of phosphatidylserine-exposing erythrocytes was significantly higher in ESRD patients (0.84 ± 0.09 %) than in healthy volunteers (0.43 ± 0.04 %) and was significantly increased immediately after dialysis (1.35 ± 0.13 %). The increase in phosphatidylserine exposure was paralleled by increase in [Ca(2+)]i, oxidative stress, and ceramide abundance. As compared to addition of plasma from healthy individuals, addition of predialytic but not of postdialytic plasma from ESRD patients increased phosphatidylserine exposure, [Ca(2+)]i, ROS, and ceramide abundance. In conclusion, both, dialyzable components of uremic plasma and dialysis procedure, trigger eryptosis at least in part by increasing erythrocyte [Ca(2+)]i, ROS, and ceramide formation. KEY MESSAGES: Anemia in uremia results in part from eryptosis, the suicidal erythrocyte death. Eryptosis in uremia is triggered in part by a dialyzable plasma component. Eryptosis in uremia is further triggered by dialysis procedure. Eryptosis in uremia is in part due to increased cytosolic Ca(2+) concentration. Eryptosis in uremia is further due to oxidative stress and ceramide formation.


Subject(s)
Erythrocytes/metabolism , Erythrocytes/pathology , Kidney Failure, Chronic/metabolism , Kidney Failure, Chronic/pathology , Adult , Aged , Aged, 80 and over , Annexin A5/metabolism , Apoptosis , Calcium/metabolism , Case-Control Studies , Cell Death , Ceramides/biosynthesis , Erythrocytes/drug effects , Female , Humans , Intracellular Space/metabolism , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/etiology , Kidney Failure, Chronic/therapy , Male , Middle Aged , Oxidative Stress , Phosphatidylserines/pharmacology , Reactive Oxygen Species/metabolism
6.
Dtsch Med Wochenschr ; 139(15): 785, 2014 Apr.
Article in German | MEDLINE | ID: mdl-24691693

ABSTRACT

HISTORY AND ADMISSION FINDINGS: A 67-year-old male patient developed progressive renal failure following successful treatment of a soft tissue sarcoma that comprised surgical resection after neoadjuvant radiochemotherapy with the application of doxorubicin (cumulative dose 180 mg/m²) and ifosfamide (cumulative dose 33 g/m²). INVESTIGATIONS: Plasma creatinine concentration was elevated to 4.5 mg/dl. Upon detection of glucosuria and α1-microglobulinuria renal biopsy was performed. DIAGNOSIS, TREATMENT AND COURSE: Histologic analysis revealed massively injured tubules that could be explained by a toxic effect of ifosfamide. Glomeruli were not affected and appeared normal. After two months of conservative therapy, the patient developed an uremic syndrome requiring hemodialysis. Ever since kidney function did not recover albeit preserved diuresis. CONCLUSIONS: Ifosfamide can cause end-stage renal disease by a tubulotoxic effect that may be the result of a selective intracellular uptake into the proximal tubule via the human organic cation transporter 2 (OCT2).


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Kidney Failure, Chronic/chemically induced , Kidney Failure, Chronic/diagnosis , Sarcoma/drug therapy , Soft Tissue Neoplasms/drug therapy , Aged , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Diagnosis, Differential , Doxorubicin/adverse effects , Doxorubicin/therapeutic use , Humans , Ifosfamide/adverse effects , Ifosfamide/therapeutic use , Male , Sarcoma/complications , Soft Tissue Neoplasms/complications , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL